EUVIMEDEUVIMED entdecken
Crossref

YTHDF3 Promotes N6‐Methyladenosine Modification of SOCS1 to Inhibit JAK1/STAT3 Pathway in the Pathogenesis of Preeclampsia

Shuang Sui iD, Xinchun Wang, Yanmei Zhang, Ying Huang iD

The Journal of Gene Medicine · 2025

DOI: 10.1002/jgm.70036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2025. Verfasst von Shuang Sui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China. Hauptthemen laut MEDLINE: Adenosine, Pre-Eclampsia, Janus Kinase 1, STAT3 Transcription Factor. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Natural Science Foundation of Xinjiang Uygur Autonomous Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preeclampsia (PE) is a common complication during pregnancy. Trophoblast cells are the main cell type of the placenta, and abnormalities in proliferation and differentiation cause anterior placental accretion and lead to the development of PE. This study will investigate the function and related mechanism of N6‐methyladenosine (m 6 A) reader YTH N6‐methyladenosine RNA binding protein F3 (YTHDF3) in PE and provide a rationale for the therapeutic treatment of PE. In the study, YTHDF3 and suppressor of cytokine signaling 1 (SOCS1) expression were significantly upregulated within PE placental tissue samples. YTHDF3 knockdown promoted the capacity of hypoxia‐treated trophoblast cells to proliferate, migrate, invade, and undergo epithelial‐mesenchymal transition (EMT) and inhibited apoptosis. The JAK1/STAT3 pathway is aberrantly activated in trophoblast cells of PE. YTHDF3 binds m 6 A‐modified SOCS1 mRNA to enhance its stability and translation. YTHDF3 / SOCS1 promotes disease progression in PE by inhibiting the JAK1/STAT3 signaling pathway. In conclusion, YTHDF3 promotes the disease progression of PE by enhancing the m 6 A modification of SOCS1 mRNA and suppressing the JAK1/STAT3 signaling pathway. YTHDF3 has been identified as an underlying target for the clinical treatment of PE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenosinePre-EclampsiaJanus Kinase 1STAT3 Transcription FactorSuppressor of Cytokine Signaling 1 ProteinRNA-Binding ProteinsHumansFemalePregnancySignal TransductionTrophoblastsCell ProliferationEpithelial-Mesenchymal TransitionApoptosisCell MovementPlacenta

Stichwörter der Autor:innen

SOCS1JAK1/STAT3 signaling pathwayN6‐methyladenosine (m6A)YTHDF3preeclampsia (PE)

Substanzen

N-methyladenosineAdenosineJanus Kinase 1STAT3 Transcription FactorSuppressor of Cytokine Signaling 1 ProteinRNA-Binding ProteinsSTAT3 protein, humanSOCS1 protein, humanJAK1 protein, human

Autor:innen und Institutionen

  • Department of Obstetrics, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.

ORCID-Profile: Shuang Sui, Ying Huang

Förderung

  • Natural Science Foundation of Xinjiang Uygur Autonomous Region

Zitieren

APA

Sui, S., Wang, X., Zhang, Y., & Huang, Y. (2025). YTHDF3 Promotes N6‐Methyladenosine Modification of SOCS1 to Inhibit JAK1/STAT3 Pathway in the Pathogenesis of Preeclampsia. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.70036

Vancouver

Sui S, Wang X, Zhang Y, Huang Y. YTHDF3 Promotes N6‐Methyladenosine Modification of SOCS1 to Inhibit JAK1/STAT3 Pathway in the Pathogenesis of Preeclampsia. The Journal of Gene Medicine. 2025. doi:10.1002/jgm.70036

BibTeX
@article{Sui2025,
  author = {Sui, Shuang and Wang, Xinchun and Zhang, Yanmei and Huang, Ying},
  title = {YTHDF3 Promotes N6‐Methyladenosine Modification of SOCS1 to Inhibit JAK1/STAT3 Pathway in the Pathogenesis of Preeclampsia},
  journal = {The Journal of Gene Medicine},
  year = {2025},
  doi = {10.1002/jgm.70036}
}
Kostenlos starten →